CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(02): 182-189
How I Treat Adult Acute Myeloid Leukemia
Authors
Tapan K. Saikia
1
Department of Medical Oncology, Prince Aly Khan Hospital, Mumbai, Maharashtra, India
Medical ,Oncology Prince Aly Khan Hospital, Mumbai, Maharashtra, India .
References
1
Arber DA,
Orazi A,
Hasserjian R.
et al. The 2016 revision to the World Health Organization classification of myeloid
neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405 2
Döhner H,
Weisdorf DJ,
Bloomfield CD.
Acute myeloid leukemia. N Engl J Med 2015; 373 (12) 1136-1152 3
Ley TJ,
Miller C,
Ding L.
et al. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of
adult de novo acute myeloid leukemia. N Engl J Med 2013; 368 (22) 2059-2074 4
Welch JS,
Ley TJ,
Link DC.
et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;
150 (02) 264-278 5
Patel JP,
Gönen M,
Figueroa ME.
et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
N Engl J Med 2012; 366 (12) 1079-1089 6
Jan M,
Snyder TM,
Corces-Zimmerman MR.
et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute
myeloid leukemia. Sci Transl Med 2012; 4 (149) 149-ra118 7
Krönke J,
Bullinger L,
Teleanu V.
et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013;
122 (01) 100-108 8
Jaiswal S,
Fontanillas P,
Flannick J.
et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J
Med 2014; 371 (26) 2488-2498 9
Sanz MA,
Grimwade D,
Tallman MS.
et al. Management of acute promyelocytic leukemia: recommendations from an expert
panel on behalf of the European LeukemiaNet. Blood 2009; 113 (09) 1875-1891 10
Osman AEG,
Anderson J,
Churpek JE.
et al. Treatment of acute promyelocytic leukemia in adults. J Oncol Pract 2018; 14
(11) 649-657 11
Lo-Coco F,
Avvisati G,
Vignetti M.
et al. Gruppo Italiano Malattie Ematologiche dell’Adulto; German-Austrian Acute Myeloid
Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide
for acute promyelocytic leukemia. N Engl J Med 2013; 369 (02) 111-121 12
Mathews V,
Chendamarai E,
George B,
Viswabandya A,
Srivastava A.
Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr
J Hematol Infect Dis 2011; 3 (01) 2011056 13
Döhner H,
Estey E,
Grimwade D.
et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an
international expert panel. Blood 2017; 129 (04) 424-447 14
Klastersky J,
de Naurois J,
Rolston K.
et al.
ESMO Guidelines Committee.
management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016;
27 (Suppl. 05) v111-v118 15
Gafter-Gvili A,
Fraser A,
Paul M,
Leibovici L.
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann
Intern Med 2005; 142 (12, pt 1) 979-995 16
Furno P,
Bucaneve G,
Del Favero A.
Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment
of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2 (04) 231-242
17
Cornely OA,
Maertens J,
Winston DJ.
et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
N Engl J Med 2007; 356 (04) 348-359 18
Mitchell S,
Li X,
Woods M.
et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent
febrile neutropenia and related complications in cancer patients in clinical practice:
a systematic review. J Oncol Pharm Pract 2016; 22 (05) 702-716 19
Mayer RJ,
Davis RB,
Schiffer CA.
et al. Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults
with acute myeloid leukemia. N Engl J Med 1994; 331 (14) 896-903 20
Sekeres MA,
Guyatt G,
Abel G.
et al. American Society of Hematology 2020 guidelines for treating newly diagnosed
acute myeloid leukemia in older adults. Blood Adv 2020; 4 (15) 3528-3549 21
Walter RB,
Othus M,
Borthakur G.
et al. Prediction of early death after induction therapy for newly diagnosed acute
myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
J Clin Oncol 2011; 29 (33) 4417-4423 22
Medeiros BC,
Satram-Hoang S,
Hurst D,
Hoang KQ,
Momin F,
Reyes C.
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia
patients in the United States. Ann Hematol 2015; 94 (07) 1127-1138 23
Juliusson G,
Antunovic P,
Derolf A.
et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes
from the Swedish Acute Leukemia Registry. Blood 2009; 113 (18) 4179-4187 24
Juliusson G,
Abrahamsson J,
Lazarevic V.
et al. Swedish AML Group and the Swedish Childhood Leukemia Group. Prevalence and
characteristics of survivors from acute myeloid leukemia in Sweden. Leukemia 2017;
31 (03) 728-731 25
Dombret H,
Seymour JF,
Butrym A.
et al. International phase 3 study of azacitidine vs conventional care regimens in
older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126 (03) 291-299
26
Othus M,
Kantarjian H,
Petersdorf S.
et al. Declining rates of treatment-related mortality in patients with newly diagnosed
AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia
2014; 28 (02) 289-292 27
Sorror M,
Storer B,
Elsawy M.
et al. Intensive versus non-intensive induction therapy for patients (pts) with newly
diagnosed acute myeloid leukemia (AML) using two different novel prognostic models.
Blood 2016; 128: 216 28
Estey EH.
Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol
2018; 93 (10) 1267-1291 29
Burnett AK,
Russell NH,
Hills RK.
et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia:
results of the medical research council AML15 trial. J Clin Oncol 2013; 31 (27) 3360-3368
30
Lee J-H,
Kim H,
Joo Y-D.
et al.
Cooperative Study Group A for Hematology.
Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction
chemotherapy foe newly diagnosed acute myeloid leukemia. J Clin Oncol 2017; 35 (24)
2754-2763 31
Löwenberg B.
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013;
121 (01) 26-28 32
Østgård LSG,
Lund JL,
Nørgaard JM.
et al. Impact of allogeneic stem cell transplantation in first complete remission
in acute myeloid leukemia: a national population-based cohort study. Biol Blood Marrow
Transplant 2018; 24 (02) 314-323 33
Elsawy M,
Sorror ML.
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant 2016; 51 (10) 1283-1300 34
Appelbaum FR.
Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients
with acute myeloid leukemia. Best Pract Res Clin Haematol 2017; 30 (04) 320-326 35
Gooley TA,
Chien JW,
Pergam SA.
et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl
J Med 2010; 363 (22) 2091-2101 36
Cornelissen JJ,
Blaise D.
Hematopoietic stem cell transplantation for patients with AML in first complete remission.
Blood 2016; 127 (01) 62-70 37
Kröger N,
Iacobelli S,
Franke GN.
et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell
transplantation for patients with myelodysplastic syndrome: a prospective randomized
phase III study of the EBMT (RICMAC trial. J Clin Oncol 2017; 35 (19) 2157-2164 38
Deeg HJ,
Stevens EA,
Salit RB.
et al. Transplant conditioning with Treosulfan/Fludarabine with or without Total body
irradiation: a randomized phase II trial in patients with myelodysplastic syndrome
and acute myeloid leukemia. Biol Blood Marrow Transplant 2018; 24 (05) 956-963 39
Scott BL,
Pasquini MC,
Logan BR.
et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for
acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2017; 35 (11) 1154-1161
40
Fasslrinner F,
Schetelig J,
Burchert A.
et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before
allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia
in first complete remission: retrospective follow-up of an open-label, randomised
phase 3 trial. Lancet Haematol 2018; 5 (04) e161-e169 41
Ivey A,
Hills RK,
Simpson MA.
et al. UK National Cancer Research Institute AML Working Group. Assessment of minimal
residual disease in standard-risk AML. N Engl J Med 2016; 374 (05) 422-433 42
Jongen-Lavrencic M,
Grob T,
Hanekamp D.
et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med
2018; 378 (13) 1189-1199 43
Salk JJ,
Schmitt MW,
Loeb LA.
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal
mutations. Nat Rev Genet 2018; 19 (05) 269-285 44
Patkar N,
Kakirde C,
Bhanshe P.
et al. Utility of immunophenotypic measurable residual disease in adult acute myeloid
leukemia- Real-World-Context. Front Oncol 2019; 9: 450 45
Schuurhuis GJ,
Heuser M,
Freeman S.
et al. Minimal/measurable residual disease in AML: a consensus document from the European
LeukemiaNet MRD Working Party. Blood 2018; 131 (12) 1275-1291 46
Riezzo I,
Pascale N,
La Russa R,
Liso A,
Salerno M,
Turillazzi E.
Donor selection for allogeneic hematopoietic stem cell transplantation: clinical and
ethical considerations. Stem Cells Int 2017; 2017: 5250790 47
Shouval R,
Fein JA,
Labopin M.
et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched
and alternative donors: a European Society for Blood and Marrow Transplantation registry
retrospective analysis. Lancet Haematol 2019; 6 (11) e573-e584 48
Kindwall-Keller TL,
Ballen KK.
Alternative donor graft sources for adults with hematologic malignancies: a donor
for all patients. Oncologist 2017; 22 (09) 1125-1134 49
Stone RM,
Mandrekar SJ,
Sanford BL.
et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation.
N Engl J Med 2017; 377 (05) 454-464 50
Voso MT,
Larson RA,
Jones D.
et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations:
a subanalysis from the RATIFY trial. Blood Adv 2020; 4 (19) 4945-4954 51
Wei AH,
Tiong IS.
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new
hope to AML. Blood 2017; 130 (23) 2469-2474 52
Burd A,
Levine RL,
Ruppert AS.
et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic
profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat
Med 2020; 26 (12) 1852-1858 53
Lai C,
Doucette K,
Norsworthy K.
Recent drug approvals for acute myeloid leukemia. J Hematol Oncol 2019; 12 (01) 100
54
Röllig C,
Serve H,
Hüttmann A.
et al.
Study Alliance Leukaemia.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years
or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase
2, randomised controlled trial. Lancet Oncol 2015; 16 (16) 1691-1699 55
Duchmann M,
Micol J-B,
Duployez N.
et al. Prognostic significance of concurrent gene mutations in intensively treated
patients with IDH-mutated AML: an ALFA study. Blood 2021; 137 (20) 2827-2837 56
Quintás-Cardama A,
Ravandi F,
Liu-Dumlao T.
et al. Epigenetic therapy is associated with similar survival compared with intensive
chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood
2012; 120 (24) 4840-4845 57
DiNardo CD,
Jonas BA,
Pullarkat V.
et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia.
N Engl J Med 2020; 383: 17-629 58
DiNardo CD,
Pollyea DA,
Jonas BA.
et al. Updated safety and efficacy of venetoclax with decitabine or azacitidine in
treatment-naïve, elderly patients with acute myeloid leukemia. Blood 2017; 130: 2628-2638
59
DiNardo CD,
Rausch CR,
Benton C.
et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy
for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Am J Hematol 2018; 93 (03) 401-407 60
Fathi AT,
DiNardo CD,
Kline I.
et al. AG221-C-001 Study Investigators. Differentiation syndrome associated with enasidenib,
a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2
study. JAMA Oncol 2018; 4 (08) 1106-1110 61
DiNardo CD,
Stein EM,
de Botton S.
et al. Durable remissions with ivosidenib in IDH-1-mutated relapsed or refractory
AML. N Engl J Med 2018; 378 (25) 2386-2398 62
Daver N,
Boddu P,
Garcia-Manero G.
et al. Hypomethylating agents in combination with immune checkpoint inhibitors in
acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2018; 32 (05) 1094-1105
63
Craddock C,
Labopin M,
Robin M.
et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem
cell transplantation for acute myeloid leukemia. Haematologica 2016; 101 (07) 879-883
64
Ghosh K,
Swaminathan S,
Madkaikar M,
Gupta M,
Kerketta L,
Vundinti B.
FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation
in tyrosine kinase domain of FLT3 gene from Western India. Ann Hematol 2012; 91 (11)
1703-1712 65
Büchner T,
Berdel WE,
Schoch C.
et al. Double induction containing either two courses or one course of high-dose cytarabine
plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation
or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24 (16)
2480-2489 66
Mao C,
Fu XH,
Yuan JQ.
et al. Interleukin-2 as maintenance therapy for children and adults with acute myeloid
leukaemia in first complete remission. Cochrane Database Syst Rev 2015; 201511 (11)
CD01 -0248 67
Oran B,
de Lima M,
Garcia-Manero G.
et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after
transplant in high-risk AML and MDS patients. Blood Adv 2020; 4 (21) 5580-5588 68
Marcucci G,
Geyer S,
Laumann K.
et al. Combination of dasatinib with chemotherapy in previously untreated core binding
factor acute myeloid leukemia: CALGB 10801. Blood Adv 2020; 4 (04) 696-705 69
Philip C,
George B,
Ganapule A.
et al. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol
2015; 170 (01) 110-117 70
Ganapule A,
Nemani S,
Korula A.
et al. Allogeneic stem cell transplantation for acute myeloid leukemia: evolution
of an effective strategy. J Glob Oncol 2017; 3 (06) 773-781 71
George B,
Menon H,
Bhurani D.
et al. A prospective observational multi-institutional study on fungal infections
following chemotherapy for acute myeloid leukemia (MISFIC Study): a real world scenario
from India. Indian J Hematol Blood Transfus 2020; 36 (01) 97-103 72
Bahl A,
Sharma A,
Raina V.
et al. Long-term outcomes for patients with acute myeloid leukemia: a single-center
experience from AIIMS, India. Asia Pac J Clin Oncol 2015; 11 (03) 242-252 73
Kalaiyarasi JP,
Ganesan P,
Kannan K.
et al. Outcomes of intensive treatment of adult acute myeloid leukemia patients: a
retrospective study from a single centre. Indian J Hematol Blood Transfus 2019; 35
(02) 248-254 74
Saikia TK,
Bakshi A,
Bhagwat R.
et al. Outcome of acute myeloid leukaemia in adults: a retrospective analysis. Natl
Med J India 2005; 18 (01) 12-15 75
Tandon N,
Banavali S,
Menon H,
Gujral S,
Kadam PA,
Bakshi A.
Is there a role for metronomic induction (and maintenance) therapy in elderly patients
with acute myeloid leukemia? A literature review. Indian J Cancer 2013; 50 (02) 154-158
76
Kapoor A,
Beniwal SK,
Kalwar A.
et al. Metronomic therapy with oral 6-mercaptourine in elderly acute myeloid leukemia.
South Asian J Cancer 2016; 5: 70-72 77
Thol F,
Schlenk RF,
Heuser M,
Ganser A.
How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015; 126
(03) 319-327 78
Burnett AK,
Goldstone A,
Hills RK.
et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation
in first remission. J Clin Oncol 2013; 31 (10) 1293-1301 79
Duval M,
Klein JP,
He W.
et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary
induction failure. J Clin Oncol 2010; 28 (23) 3730-3738 80
Cummins KD,
Gill S.
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to
reality. ? Haematologica 2019; 104 (07) 1302-1308 81
Halpern AB,
Lyman GH,
Walsh TJ,
Kontoyiannis DP,
Walter RB.
Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.
Blood 2015; 126 (26) 2790-2797
